Adiponectin Inhibits Hyperlipidemia-Induced Platelet Aggregation via Attenuating Oxidative/Nitrative Stress

W.-Q. WANG¹, H.-F. ZHANG², G.-X. GAO¹, Q.-X. BAI¹, R. LI³, X.-M. WANG³

¹Department of Hematology, Tangdu Hospital, Fourth Military Medical University, Xi’an, China, ²Department of Physiology, Xijing Hospital, Fourth Military Medical University, Xi’an, China, ³Department of Geriatrics, Xijing Hospital, Fourth Military Medical University, Xi’an, China

Received June 10, 2010
Accepted August 30, 2010
On-line November 29, 2010

Summary
Adiponectin acts as an endogenous antithrombotic factor. However, the mechanisms underlying the inhibition of platelet aggregation by adiponectin still remain elusive. The present study was designed to test whether adiponectin inhibits platelet aggregation by attenuation of oxidative/nitrative stress. Adult rats were fed a regular or high-fat diet for 14 weeks. The platelet was immediately separated and stimulated with recombinant full-length adiponectin (rAPN) or not. The platelet aggregation, nitric oxide (NO) and superoxide production, endothelial nitric oxide synthase (eNOS)/inducible NOS (iNOS) expression, and antioxidant capacity were determined. Treatment with rAPN inhibited hyperlipidemia-induced platelet aggregation (P<0.05). Interestingly, total NO, a crucial molecule depressing platelet aggregation and thrombus formation, was significantly reduced, rather than increased in rAPN-treated platelets. Treatment with rAPN markedly decreased superoxide production (-62 %, P<0.05) and enhanced antioxidant capacity (+38 %, P<0.05) in hyperlipidemic platelets. Hyperlipidemia-induced reduced eNOS phosphorylation and increased iNOS expression were significantly reversed following rAPN treatment (P<0.05, P<0.01, respectively). Taken together, these data suggest that adiponectin is an adipokine that suppresses platelet aggregation by enhancing eNOS activation and attenuating oxidative/nitrative stress including blocking iNOS expression and superoxide production.

Key words
Adiponectin • Platelet • Aggregation • Hyperlipidemia

Introduction
Metabolic syndrome (MS) is characterized by a series of metabolic and hemodynamic alterations, which increase the incidence of endothelial damage and atherosclerosis, becoming the leading cause of cardiovascular disease (Hulthe et al. 2000, Sakkinen et al. 2000). Hyperlipidemia, the critical component of metabolic syndrome, is closely related to atherosclerosis and formation of thrombus. Dyslipidemia is accompanied by platelet hyperactivity, hypercoagulability with increased factor VII, and hypofibrinolysis with increased plasminogen activator inhibitor PAI-1 (Juhan-Vague and Vague 1990). The increased flux of nonesterified fatty acids (NEFAs) from the adipocytes increases tissue factor (TF) and PAI-1 levels and enhances platelet aggregation; all of these obviously promote the development of thrombosis (Eckel et al. 2002).

Adiponectin is a cytokine predominantly secreted from adipose tissue and abundantly present in plasma. Numerous studies have shown that plasma levels of adiponectin decrease in obesity, type 2 diabetes, and patients with coronary artery disease (CAD) (Hotta et al. 2000, Matsuzawa et al. 2004). In adiponectin knockout (APN-KO) male mice, an accelerated thrombus formation has been observed. Adenovirus-mediated supplementation of adiponectin attenuates the enhanced thrombus formation (Kato et al. 2006). Decreased adiponectin serum levels in patients with essential hypertension correlate well with changes in ADP-induced platelet aggregation (Ekmecki et al. 2009). This association may potentially contribute to future thrombus formation and
higher risks for cardiovascular events in such patients. These data suggest that adiponectin acts as an endogenous antithrombotic factor. However, the mechanisms underlying the inhibition of platelet aggregation by adiponectin still remain largely elusive.

Platelet activation occurs through the stimulation of a large number of exquisitely integrated positive signaling pathways that ensure their rapid activation at sites of vascular injury. Platelets may also generate nitric oxide (NO), although both the presence of NO synthase (NOS) and the role of platelet-derived NO are controversial (Naseem and Riba 2008). It was suggested that platelet-derived NO depresses platelet aggregation and thrombus formation (Freedman et al. 1997, 1999). At the same time, platelet-derived NO has been suggested to be a critical component of the platelet activation pathway in response to von Willebrand factor (VWF) and thrombin (Li et al. 2003, 2006). Regardless of the role of NO, all of these studies agree that NO mediates platelet actions through the stimulation of soluble guanylate cyclase (sGC) and downstream activation of PKG, although they may be critical for the interpretation of the potential role of these related enzymes in platelets. Furthermore, to the best of our knowledge, the possibility that adiponectin may play a crucial role in protection of vasculature from hyperlipidemia-promoted platelet aggregation and thrombosis formation has never been studied.

In this study, we have provided the first evidence that as an antithrombotic factor, adiponectin inhibits hyperlipidemia-induced platelet aggregation via eNOS/NO pathway.

Material and Methods

Animals

All the experimental procedures were in accordance with the National Institutes of Health guidelines and were approved by the local authorities for animal research. Twenty male Sprague-Dawley rats (8 weeks old) were randomized to receive a regular chow diet or a high-fat supplemented diet (detailed composition: 1 % cholesterol, 10 % lard, 10 % yolk powder, 0.2 % porcine cholate, 78.8 % regular chow). Food and water were provided ad libitum, and animals were maintained in a temperature-controlled barrier facility with a 12:12-h light-dark cycle. Fourteen weeks later, animals were anesthetized by intraperitoneal administration of 20 % urethane. Caval blood was withdrawn, the platelet was immediately separated, and lipid profile, glucose, and insulin levels were determined as described below.

Plasma lipid determinations

Plasma cholesterol and triglyceride levels were determined by a biochemistry analyzer (Cobas Integra 400 Plus, Roche) in accordance with the manufacturer’s instructions.

Isolation of rat platelets

Rat platelets were isolated by the method described previously (Riba et al. 2008). Briefly, caval blood was taken using acid citrate dextrose (ACD: 29.9 mM sodium citrate, 113.8 mM glucose, 72.6 mM NaCl, 2.9 mM citric acid, pH 6.4) as anticoagulant. Platelet-rich plasma (PRP) was obtained by centrifugation of whole blood at 200 g for 20 min. Washed platelets (WP) were isolated from PRP by centrifugation at 800 g for 12 min in the presence of prostaglandin E1 (PGE1; 50 ng/ml). The platelet pellet was resuspended at a concentration of 2×10^8 platelets/ml in modified Tyrodes buffer (150 mM NaCl, 5 mM HEPES, 0.55 mM NaH2PO4, 7 mM NaHCO3, 2.7 mM KCl, 0.5 mM MgCl2, 5.6 mM glucose, pH 7.4).

Platelet aggregation

Platelet aggregation was analyzed by a improved turbidimetric method (Born 1962). Tyrode solution was used to adjust the baseline of minimal light transmission. Platelet aggregation was recorded under constant stirring conditions (900 rpm, 6 min) in optical density (OD) by platelet aggregation system (Shanghai Record Instrument, China). In brief, rat WP (2×10^8/ml) were placed in 20-well cell culture plates, stimulated at 37 °C with vehicle or 10 μg/ml recombinant full-length adiponectin (rAPN, BioVendor Laboratory Medicine, Czech Republic) for one hour, the fall in absorbance of washed platelets being determined 1-5 min after addition of a standard amount of aggregating agent thrombin (1 IU/ml). A portion of rAPN-treated platelets was pre-incubated with L-arginine (L-NMMA; 1 mM) for 10 min. Each treatment group consisted of 5 wells of platelets.

The percentage of aggregation was calculated by the formula, where absorbance was measured by optical density (OD): % aggregation=([OD before the addition of thrombin – OD after the addition of thrombin]/[OD before the addition of thrombin – OD of Tyrode...
solution]×100. All studies were performed at least twice on two separate occasions in triplicate, and the data with standard deviations within 10 % of the mean are reported (Chia et al. 2004).

Platelet aggregation was also examined by using a fluorescence microscopy and followed immunofluorescence detection procedures described previously (Karpman et al. 2001). Treated platelets were fixed with 1 % paraformaldehyde at 25 °C for 30 min. After fixation, platelets were seeded onto glass slides. Coated glass slides were washed three times with PBS, and fluorescein isothiocyanate (FITC)-conjugated rabbit anti-rat CD9 monoclonal antibody was added and incubated at 37 °C for 1 h. Slides were washed four times in PBS, and covered with a fluorescent mounting gel (Biomed, Vancouver, Canada) before being examined under an immunofluorescence microscope. For each slide, 10 fields were randomly chosen and using a defined rectangular field area (20× objective), a total of 100 platelets per field were counted. The aggregation index was determined. The assays were performed in a blinded manner.

**Total NO production measurement**

Platelet total NO production was determined by measuring the concentration of nitrite, a stable metabolite of NO *in vitro*, with a modified Griess reaction method (Cosentino et al. 1997). Briefly, control platelets or hyperlipidemic platelets were stimulated with vehicle, rAPN (10 μg/ml), or rAPN plus L-NMMA as above, 100 μl of culture medium was taken and mixed with an equal volume of modified Griess reagent (1 % sulfanilamide, 0.1 % naphthylethylenediamine dihydrochloride, and 2 % phosphoric acid). After 10 min of incubation at room temperature, the resultant chromophore was spectrophotometrically determined at 540 nm using a spectrophotometer (Spectra-Max 190, Molecular Device). The nitrite concentrations in the samples were calculated from freshly prepared nitrite standard curves made from sodium nitrite with the same medium.

**Determination of eNOS and iNOS expression by Western blot**

Platelets were sonicated in lysis buffer. After quantitation of protein content with Bradford protein assay, equal amounts of protein (40 μg protein/lane) were electrophoresed on a 14 % SDS-polyacrylamide gel and electrophoretically transferred to a poly(vinylidene difluoride) membrane (Millipore, Billerica, MA). After blocking with 5 % skim milk in Tris-buffered saline at room temperature for 1 h, the membrane was incubated with an antibody against eNOS, phosphorylated eNOS (Ser-1177), or iNOS (Cell Signaling Technology, Danvers, MA) overnight at 4 °C. The membrane was then washed with PBS and incubated with horseradish peroxidase-conjugated IgG antibody (Cell Signaling) for 1 h at 37 °C. The blots were developed with an enhanced chemiluminescence detection kit (Pierce Biotechnology, Rockford, IL). The immunoblotting was visualized with ChemiDocXRS (Bio-Rad Laboratory, Hercules, CA), and the blot densities were analyzed with LabImage software.

**Determination of platelets antioxidant capacity**

Platelets were sonicated in 0.9 % NaCl solution (1:10, wt/vol), and centrifuged at 3000 g for 5 min. The pellet was discarded. Total antioxidant capacity was determined with a spectrophotometric assay kit (Nanjing Jiancheng Bioengineering Institute), following the manufacturer’s instruction. In brief, 30 μl of supernatant was added to the reaction buffer containing xanthine, xanthine oxidase, and hydroxylamine. After 40 min of incubation at 37 °C, accumulation of nitrite was quantified by the Griess reaction. Platelets antioxidant capacity is inversely related to the concentration of nitrate. Results were normalized against the mean value of control and expressed as fold changes.

**Quantification of platelets superoxide production**

Superoxide production from platelets was measured by flow injection chemiluminescence as described previously (Yao et al. 2004). Superoxide production was expressed as chemiluminescence intensity (CI) per microgram of protein (CI/μg protein).

**Statistical analysis**

Values are presented as means ± S.E.M. Data were analyzed with one-way ANOVA (GraphPad Software, San Diego, CA). A probability value of *P*<0.05 was considered to be statistically significant.

**Results**

**Plasma lipid profile**

Total cholesterol and triglyceride levels were found to be significantly higher in HF fed rats than those fed with control diet (2.0±0.1 vs 1.6±0.1, *P*<0.01 and 1.5±0.3 vs 1.1±0.3, *P*<0.05, respectively, *n*=8-10 animals/group).
Treatment with rAPN inhibited hyperlipidemia-induced platelet aggregation

As illustrated in Figure 1, hyperlipidemia caused a significant increase in platelet aggregation after 5 min treatment with thrombin ($P<0.01$). However, pretreatment with rAPN for 1 h markedly reduced the hyperlipidemic platelet aggregation ($P<0.05$). To determine whether rAPN inhibited thrombin-induced platelet aggregation by enhancing NO production, a portion of rAPN-treated platelets was pretreated with L-NMMA. Addition of 1 mM L-NMMA prior to rAPN dramatically inhibited rAPN effects on platelet aggregation ($P<0.01$). Furthermore, fluorescence microscopy revealed an enhanced aggregation in hyperlipidemic platelets compared to control platelets ($P<0.05$, Fig. 2). The treatment with rAPN moderately reduced the aggregation of hyperlipidemic platelets ($P<0.05$). However, platelet aggregation was significantly enhanced after addition of L-NMMA ($P<0.01$).

Treatment with rAPN decreased hyperlipidemia-induced NO overproduction

NO has been shown to be responsible for endothelium-dependent vasorelaxation and inhibition of platelet adhesion and aggregation (Riddell and Owen 1999). We attempted to obtain a direct evidence that treatment with rAPN may increase NO production and thus inhibit hyperlipidemia-induced platelet aggregation. Surprisingly, although treatment of platelets with rAPN significantly decreased platelet aggregation, this treatment also reduced total NO production ($P<0.05$, Fig. 3). This paradoxical result suggests that more complex signaling mechanisms are involved in the protective effect of rAPN against hyperlipidemia-induced platelet aggregation.

Treatment with rAPN increased eNOS phosphorylation and reduced iNOS expression in hyperlipidemic platelets

Although adiponectin has been shown to stimulate NO production in cultured platelets by
phosphorylating eNOS (Milward et al. 2006), the treatment with rAPN did not increase but reduced total NO production in hyperlipidemic platelets (Fig. 3). These results suggest that the overall effect of rAPN on total NO production may involve a complex regulation of rAPN on different forms of NOS under hyperlipidemic conditions. To investigate directly this novel possibility, the effect of rAPN on eNOS phosphorylation and iNOS expression was determined. As summarized in Figure 4, a significant reduction in eNOS phosphorylation ($P<0.05$) and a marked increase in iNOS expression ($P<0.01$) were observed in hyperlipidemic platelets. Pretreatment with rAPN almost completely normalized eNOS phosphorylation ($P<0.05$) and significantly reduced iNOS expression ($P<0.01$) in hyperlipidemic platelets. These results demonstrated that rAPN had opposite effects on p-eNOS and iNOS expression, and this differential regulatory role may explain the paradoxical finding that rAPN significantly inhibited platelet aggregation but reduced total NO production.

**Treatment with rAPN significantly reduced superoxide overproduction and enhanced antioxidant capacity in hyperlipidemic platelets**

The above-mentioned results demonstrated that overproduction of NO in hyperlipidemic platelets is due to overexpression of iNOS protein. However, increase in NO production failed to inhibit platelet aggregation, suggest that increased NO destruction may be responsible for hyperlipidemic platelet aggregation. In addition, our novel observation that rAPN inhibited platelet aggregation without increasing NO production indicates that rAPN may reduce platelet aggregation by preserving bioactive NO. To obtain direct evidence to support this hypothesis, additional experiments were performed. As summarized in Figure 5A, a 2.5-fold increase in superoxide production was observed in platelets isolated from hyperlipidemic animals, and treatment with rAPN almost abolished (62% reduction compared with vehicle-treated platelets, $P<0.05$) the superoxide overproduction observed in hyperlipidemic platelets. Moreover, hyperlipidemia-induced reduction in total antioxidant capacity was significantly preserved after rAPN treatment (38 % increase compared with vehicle-treated platelets, $P<0.05$, Fig. 5B).

**Discussion**

The present study yields several important new observations. First, we have observed for the first time that acute treatment with rAPN significantly attenuated hyperlipidemia-induced platelet aggregation. Second, we
have provided a direct evidence that inhibition of superoxide production, suppression of iNOS-mediated NO overproduction and protection of NO from destruction are the major mechanisms by which adiponectin exerts its antithrombotic effect. This result not only provides additional evidence that reduced adiponectin in metabolic disorders contributes to the formation of thrombus, but raises the possibility that therapeutic application of rAPN may be a useful treatment of metabolic disorders with atherosclerosis.

The close correlations among obesity, the metabolic syndrome, and atherosclerosis are well established (Cooper-DeHoff and Pepine 2007). However, mechanisms by which obesity promotes the occurrence of thrombus are not well understood. Increasing attention has been paid to the direct antithrombotic effects of plasma proteins that originate from adipose tissue, especially adiponectin (Goldstein and Scalia 2004). Decreased plasma adiponectin levels are observed in patients with diabetes, metabolic syndrome, and coronary artery disease (Ouchi et al. 2006). Moreover, many studies in animal models and human subjects have demonstrated that adiponectin is a critical anti-atherosclerotic molecule whose reduction may contribute to thrombus formation and platelet aggregation (Kato et al. 2006, Ekmekci et al. 2009). The present study took a different approach and provided the first evidence that acute treatment with rAPN significantly attenuated platelet aggregation associated with hyperlipidemia. In contrast with our results, Riba et al. (2008) reported that recombinant globular domain of adiponectin (gAd), but not rAPN, stimulates platelet aggregation through tyrosine kinase-dependent signaling pathway. Different effects of various isoforms of adiponectin on platelet aggregation raise the possibility that they may have distinct receptors and activate specific pathway, respectively.

We have obtained several lines of evidence indicating that rAPN inhibits platelet aggregation by its novel antioxidative property. First, adiponectin significantly reversed the hyperlipidemia-induced reduction of antioxidant activity. Since either increased formation of antioxidant molecules or reduced expression of oxidant molecules can strengthen antioxidant activity, we detected adiponectin effect on superoxide production. Consistent with the study by Sanguigni et al. (2002), superoxide production was increased in hyperlipidemic platelets, and we further observed the overexpression of superoxide, which was markedly suppressed by adiponectin administration. It is well documented that superoxide reacts with NO at a near diffusion-limited rate, which is three times faster than the reaction between superoxide and superoxide dismutase (Huie and Padmaja 1993). This reaction not only causes the inactivation of NO, a molecule depressing leucocyte adhesion and platelet aggregation, but also results in the formation of peroxynitrite anion (ONOO•), a highly reactive and cytotoxic molecule (Beckman and Koppenol 1996). Thus the superoxide/NO reaction is a “toxic switch” that plays a critical pathogenic role in the development of thrombus.

Human platelets possess the L-arginine-NO pathway through constitutive NO synthase (Sase and Michel 1995). There is accumulating evidence to show that NO suppresses platelet aggregation and activation (Gkaliagkousi et al. 2007). Previous studies in cultured endothelial cells or platelets have demonstrated that adiponectin activates eNOS and increases NO production (Chen et al. 2003, Li et al. 2003). Surprisingly, our results indicated adiponectin treatment reduced NO production, although it enhanced eNOS activation. Finally we found that hyperlipidemia induced overexpression of iNOS, which has the ability to produce excessive NO, and the treatment with adiponectin suppressed iNOS expression in hyperlipidemic platelets. Since under the conditions of oxidative stress, NO undergoes a rapid reaction with superoxide anions to form peroxynitrite, a toxic metabolite of NO, which could cause platelet dysfunction (Redondo et al. 2005, Olas and Wachowicz 2007), it is conceivable that adiponectin inhibits platelet activation by suppressing the inactivation of NO and subsequent formation of peroxynitrite via its antioxidative properties.

In summary, the present study demonstrated for the first time that adiponectin is an adipokine that suppresses platelet aggregation and activation by enhancing eNOS activation and attenuates oxidative/nitrative stress by blocking iNOS expression and superoxide production. Loss of this dual-protective effect of adiponectin because of reduced adiponectin production and/or development of adiponectin resistance in patients with metabolic syndrome may play a critical pathogenic role in thrombus formation and atherosclerosis. If these effects were proved by treating the diet-fed rats with rAPN in vivo, this would significantly strengthen the present in vitro data.

Conflict of Interest
There is no conflict of interest.
Acknowledgements
This research was supported by the following grants: National Natural Science Foundation of China (No.30700308 to R. Li).

Abbreviations
ACD – acid citrate dextrose; APN-KO – adiponectin knockout; CAD – coronary artery disease; eNOS – endothelial nitric oxide synthase; FITC – fluorescein isothiocyanate; gAd – globular domain of adiponectin; iNOS – inducible nitric oxide synthase; L-NMMA – N°-monomethyl-L-arginine; MS – metabolic syndrome; NEFAs – nonesterified fatty acids; NO – nitric oxide; OD – optical density; ONOO− – peroxynitrite anion; PAI – plasminogen activator inhibitor; PGE1 – prostaglandin E1; PKG – protein kinase G; PRP – platelet-rich plasma; rAPN – recombinant full-length adiponectin; sGC – soluble guanylate cyclase; TF – tissue factor; VWF – von Willebrand factor; WP – washed platelets.

References


